HighTower Advisors’s AbbVie ABBV Stock Holding History

HighTower Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,500	Closed	-$128K	–	3668
2024 Q1	$128K	Buy	+34,500	New	+$5.95M	﹤0.01%	3096
2022 Q2	–	Sell	-16	Closed	-$21K	–	3219
2022 Q1	$21K	Buy	+16	New	+$2.32K	﹤0.01%	3159
2019 Q3	–	Sell	-200	Closed	-$2K	–	2404
2019 Q2	$2K	Buy	+200	New	+$15.7K	﹤0.01%	2344

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

HighTower Advisors's ABBV Position: Q2 2026 in Review

HighTower Advisors increased its AbbVie (ABBV) stake by 19% in Q2 2026, buying an estimated $66.5M and bringing the position to 1,967,343 shares worth $495M. The position accounts for 0.48% of the portfolio, ranked #35.

HighTower Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

HighTower Advisors held 1,967,343 shares of AbbVie worth $495M as of Q2 2026.
HighTower Advisors bought 309,319 AbbVie shares in Q2 2026, an estimated $66.5M.
AbbVie made up 0.48% of HighTower Advisors's portfolio in Q2 2026, its #35 holding.
HighTower Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.